REGN
Regeneron Pharmaceuticals, Inc.
Stock
$735.20+0.39 (+0.05%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.7B | $5.0B | $4.4B | $4.6B | $5.0B | $7.1B | $2.6B | $2.4B | $2.2B | $1.3B | $1.5B | $1.3B | $752M | $589M | −$75M | −$142M | $99M | −$70M | −$89M |
| Capital expenditures | $921M | $898M | $756M | $719M | $590M | $552M | $615M | $430M | $383M | $273M | $512M | $678M | $333M | $156M | $49M | $57M | $100M | $97M | $35M |
| Free cash flow | $3.8B | $4.1B | $3.7B | $3.9B | $4.4B | $6.5B | $2.0B | $2.0B | $1.8B | $1.0B | $974M | $653M | $419M | $432M | −$124M | −$199M | −$467K | −$167M | −$124M |
| Stock-based compensation | $987M | $994M | $983M | $885M | $725M | $602M | $432M | $464M | $427M | $507M | $560M | $459M | $322M | $215M | $94M | $56M | $40M | $31M | $33M |
| Buybacks | $3.3B | $3.4B | $2.6B | $2.2B | $2.1B | $1.6B | $5.8B | $276M | $4.4M | $0 | $0 | — | — | — | — | — | — | — | — |
| Dividends paid | $379M | $370M | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends per share | $3.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free cash flow margin | 24.2% | 28.4% | 25.8% | 29.5% | 36.3% | 40.6% | 23.6% | 30.5% | 35.2% | 17.6% | 20.0% | 15.9% | 14.9% | 20.5% | −9.0% | −44.6% | −0.1% | −44.1% | −52.0% |